The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells

Journal of Chemotherapy

Volumn 10, Issue 1, 1998, Pages 7-16

  Fratti, R A ^a   Belanger, R H ^a   Sanati, H ^a   Ghannoum, M A ^b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungals; Candida albicans; Candida krusei; Endothelial cells; Fluconazole; Fungi; Triazole; Voriconazole

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CELL ADHESION; CELL DAMAGE; COCULTURE; CONTROLLED STUDY; DRUG RESISTANCE; ENDOTHELIUM CELL; GERMINATION; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; STRAIN DIFFERENCE;

EID: 0031888968     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.1.7     Document Type: Article

References (23)

1. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995; 21: 897-904.
2. Ghannoum MA, Radwan SS. The adherence process. In: Candida Adherence to Epithelial cells. Boca Raton, Florida CRC Press, 1990: 105-169.
3. Andersen ML, Odds FC. Adherence of Candida albicans to vaginal epithelia: significance of morpholopgical form and effect of ketoconazole. Mykosen 1985; 28: 531-540.
4. Ghannoum MA, Abu Elteen K. Correlative relationship between proteinase production, adherence and pathogenicity of various strains of Candida albicans. J Med Vet Mycol 1986; 24: 407-413.
5. Ghannoum MA, Filler SG, Ibrahim AS, Fu Y, Edwards Jr JE. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother 1992; 36: 2239-2244.
6. Liss RH, Letoumeau RJ. Fungispecificity of fluconazole against Candida albicans. Mycopathologia 1989; 108: 173-178.
7. Macura AB. The influence of some antifungal drugs on in vitro adherence of Candida albicans to human buccal epithelial cells. Mycoses 1988; 31: 371-376.
8. Sobel JD, Obedeanu N. Effects of sub-inhibitory concentrations of ketoconazole on in vitro adherence of Candida albicans to vaginal epithelial cells. Eur J Clin Microbiol 1983; 2: 445-452.
9. Yeaman MR, Sullam PM, Dazin PF, Ghannoum MA, Edwards JE, Bayer AS. Fuconazole and platelet microbicidal protein inhibit Candida adherence to platelets in vitro. Antimicrob Agents Chemother 1994; 38: 1460-1465.
10. Hitchcock CA, Pye GW, Oliver GP, Troke PF. UK-109,496: a novel, wide spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC, 1995: Abstr. # F72, p. 125.
11. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-1842.
12. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492-2496.
13. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-242.
14. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; tentative standard, M27T. National Committee for Clinical Laboratory Standards, Wayne, Pa, 1995.
15. Jaffe EA, Nachman RL, Becker CG, Ninick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologie criteria. J Clin Invest 1973; 52: 2745-2756.
16. Ghannoum MA, Abu Elteen K, Ellabib M, Whittaker PA. Antimycotic effects of cotenidine and pirtenidine. J Antimicrob Chemother 1990; 25: 237-245.
17. Ibrahim AS, Filler SG, Ghannoum MA, Edwards Jr JE. Interferon-gamma protects endothelial cells from damage by Candida albicans. J Infect Dis 1993; 167: 2239-2244.
18. Abu El Teen K, Ghannoum M, Stretton RJ. Effects of sub-inhibitory concentrations of antifungal agents adherence of Candida spp. to buccal epithelial cells in vitro. Mycoses 1989; 32: 551-562.
19. Brenciaglia MI, Ghezzi MC, Cipriani P, Mancini C, Trancassini M. The influence of antifungal drugs on adherence of C. albicans to buccal epithelial cells. Chemioterapia 1986; 5: 200-203.
20. Mehentee JF, Hay RJ. Effect of antifungal agents on the adherence of Candida albicans to murine gastrointestinal mucosal surfaces. J Antimicrob Chemother 1990; 25: 111-119.
21. Van 't Wout JW, Meynaar I, Linde I, Poell R, Matti H, Van Fuerth R. Effect of amphotericin B, fluconazole, and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J Antimicrob Chemother 1990; 25: 803-811.
22. Ghannoum MA, Radwan SS. Pathogenicity determinants in Candida. In: Candida Adherence to Epithelial cells. Boca Raton, Florida, CRC Press, 1990: 71-104.
23. Johnson EM, Warnock DW, Richardson MD, Douglas CJ. In-vitro effect of itraconazole, ketoconazole, and amphotericin B on phagocytic and candidacidal function of human neutrophils. J Antimicrob Chemother 1986; 18: 83-91.